Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Emricasan (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms ENCORE-NF
- Sponsors Conatus Pharmaceuticals
- 27 Dec 2019 Results published in the Journal of Hepatology
- 02 May 2019 Primary endpoint has not been met. (Fibrosis improvement by at least one stage without worsening of steatohepatitis), according to a Conatus Pharmaceuticals media release.
- 21 Mar 2019 Status changed from active, no longer recruiting to completed, according to a Conatus Pharmaceuticals media release.